RU98106117A - RECOMBINANT ANTIBODIES AGAINST CD4 FOR HUMAN THERAPY - Google Patents

RECOMBINANT ANTIBODIES AGAINST CD4 FOR HUMAN THERAPY

Info

Publication number
RU98106117A
RU98106117A RU98106117/13A RU98106117A RU98106117A RU 98106117 A RU98106117 A RU 98106117A RU 98106117/13 A RU98106117/13 A RU 98106117/13A RU 98106117 A RU98106117 A RU 98106117A RU 98106117 A RU98106117 A RU 98106117A
Authority
RU
Russia
Prior art keywords
chimeric antibody
autoimmune disorder
aforementioned
recombinant dna
antibody according
Prior art date
Application number
RU98106117/13A
Other languages
Russian (ru)
Other versions
RU2232773C2 (en
Inventor
Ханна Нэйбил
Э.Ньюман Роланд
Э.Рефф Митчелл
Original Assignee
Айдек Фармасьютикалз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/523,894 external-priority patent/US6136310A/en
Application filed by Айдек Фармасьютикалз Корпорейшн filed Critical Айдек Фармасьютикалз Корпорейшн
Publication of RU98106117A publication Critical patent/RU98106117A/en
Application granted granted Critical
Publication of RU2232773C2 publication Critical patent/RU2232773C2/en

Links

Claims (1)

1. Химерное антитело, специфическое в отношении CD4 человека, которое практически не имеет истощающей Т-клетки активности, которое содержит последовательности вариабельного домена тяжелой и легкой цепей моноклонального антитела низшей узконосой обезьяны, продуцируемого против CD4 человека, и последовательности константного домена тяжелой и легкой цепей антитела человека.1. Chimeric antibody specific for human CD4, which has virtually no T-cell depleting activity, which contains the sequences of the variable domain of the heavy and light chains of the monoclonal antibody of the lower narrow-nosed monkey produced against human CD4, and the sequence of the constant domain of the heavy and light chains of the antibody person. 2. Химерное антитело по п.1, где последовательности константного домена тяжелой цепи человека выбраны из (1) немодифицированных константных доменов изотипа гамма 4 человека; (2) константных доменов изотипа гамма 4, которые были модифицированы мутагенезом для уменьшения связывания комплемента, связывания рецептора Fcγ1 и/или усиления стабильности; и (3) константных доменов изотипа гамма 4, мутированных в положении 236 заменой глутаминовой кислоты лейцином и/или в положении 229 заменой пролина серином. 2. The chimeric antibody of claim 1, wherein the sequences of the constant domain of the human heavy chain are selected from (1) unmodified constant domains of the human gamma 4 isotype; (2) gamma 4 isotype constant domains that have been modified by mutagenesis to reduce complement binding, Fcγ1 receptor binding and / or stability enhancement; and (3) gamma 4 isotype constant domains mutated at position 236 by replacing glutamic acid with leucine and / or at position 229 by replacing proline with serine. 3. Химерное антитело по п.1, где вышеупомянутые вариабельные антигенсвязывающие последовательности тяжелой и легкой цепей представлены в фиг.1 и фиг.2. 3. The chimeric antibody according to claim 1, where the aforementioned variable antigen binding sequences of the heavy and light chains are presented in figure 1 and figure 2. 4. Химерное антитело по п.1, которое обладает одним или несколькими из следующих свойств: (i) не имеет активности связывания Fc-рецептора (или обнаруживает пониженную активность связывания Fc-рецептора) по сравнению с химерными антителами изотипа γ1; (ii) проявляет пониженную способность связывания комплемента (или ее отсутствие) и (iii) проявляет измененный фармакокинетический профиль. 4. The chimeric antibody according to claim 1, which has one or more of the following properties: (i) does not have Fc receptor binding activity (or detects reduced Fc receptor binding activity) compared to chimeric antibodies of isotype γ1; (ii) exhibits a reduced complement binding ability (or lack thereof); and (iii) exhibits an altered pharmacokinetic profile. 5. Химерное антитело по п.1, которое изменяет или регулирует связанные с CD4 иммунные функции, в том числе индукцию анергии и апоптоза в Т-клетках. 5. The chimeric antibody of claim 1, which modifies or regulates CD4-related immune functions, including the induction of anergy and apoptosis in T cells. 6. Химерное антитело против CD4, которое выбрано из группы, состоящей из CE9γ4, CE9γ4λK, CE9γ4E и CE9γ4PE.
7. Рекомбинантная ДНК, кодирующая химерное антитело по п.1.6. Chimeric anti-CD4 antibody, which is selected from the group consisting of CE9γ4, CE9γ4λK, CE9γ4E and CE9γ4PE.
7. Recombinant DNA encoding a chimeric antibody according to claim 1. 8. Рекомбинантная ДНК, кодирующая химерное антитело по п.2. 8. Recombinant DNA encoding a chimeric antibody according to claim 2. 9. Рекомбинантная ДНК, кодирующая химерное антитело по п.3. 9. Recombinant DNA encoding a chimeric antibody according to claim 3. 10. Рекомбинантная ДНК, кодирующая химерное антитело по п. 4. 10. Recombinant DNA encoding a chimeric antibody according to claim 4. 11. Рекомбинантная ДНК, которая кодирует и обеспечивает экспрессию химерного антитела по п.6. 11. Recombinant DNA that encodes and provides expression of a chimeric antibody according to claim 6. 12. Способ получения химерного антитела, специфического в отношении CD4, предусматривающий экспрессию рекомбинантной ДНК по п.7 в рекомбинантной клетке-хозяине. 12. A method of producing a chimeric antibody specific for CD4, comprising expressing the recombinant DNA according to claim 7 in a recombinant host cell. 13. Способ получения химерного антитела, специфического в отношении CD4, предусматривающий экспрессию рекомбинантной ДНК по п.8 в рекомбинантной клетке-хозяине. 13. A method of producing a chimeric antibody specific for CD4, comprising expressing the recombinant DNA of claim 8 in a recombinant host cell. 14. Способ получения химерного антитела, специфического в отношении CD4, предусматривающий экспрессию рекомбинантной ДНК по п.9 в рекомбинантной клетке-хозяине. 14. A method for producing a chimeric antibody specific for CD4, comprising expressing the recombinant DNA of claim 9 in a recombinant host cell. 15. Способ получения химерного антитела, специфического в отношении CD4, предусматривающий экспрессию рекомбинантной ДНК по п.10 в рекомбинантной клетке-хозяине. 15. A method of producing a chimeric antibody specific for CD4, comprising expressing the recombinant DNA of claim 10 in a recombinant host cell. 16. Способ получения химерного антитела, специфического в отношении CD4, предусматривающий экспрессию рекомбинантной ДНК по п.11 в рекомбинантной клетке-хозяине. 16. A method of producing a chimeric antibody specific for CD4, comprising expressing the recombinant DNA of claim 11 in a recombinant host cell. 17. Способ лечения или предотвращения связанного с CD4 состояния, предусматривающий введение терапевтически или профилактически эффективного количества химерного антитела по п. 1. 17. A method of treating or preventing a CD4-related condition, comprising administering a therapeutically or prophylactically effective amount of a chimeric antibody according to claim 1. 18. Способ лечения или предотвращения связанного с CD4 состояния, предусматривающий введение терапевтически или профилактически эффективного количества химерного антитела по п.2. 18. A method for treating or preventing a CD4-related condition, comprising administering a therapeutically or prophylactically effective amount of a chimeric antibody according to claim 2. 19. Способ лечения или предотвращения связанного с CD4 состояния, предусматривающий введение терапевтически или профилактически эффективного количества химерного антитела по п.3. 19. A method of treating or preventing a CD4-related condition, comprising administering a therapeutically or prophylactically effective amount of a chimeric antibody according to claim 3. 20. Способ лечения или предотвращения связанного с CD4 состояния, предусматривающий введение терапевтически или профилактически эффективного количества химерного антитела по п. 4. 20. A method of treating or preventing a CD4-related condition, comprising administering a therapeutically or prophylactically effective amount of a chimeric antibody according to claim 4. 21. Способ лечения или предотвращения связанного с CD4 состояния, предусматривающий введение терапевтически или профилактически эффективного количества химерного антитела по п.6. 21. A method for treating or preventing a CD4-related condition comprising administering a therapeutically or prophylactically effective amount of a chimeric antibody according to claim 6. 22. Способ по п.16, где связанным с CD4 состоянием является аутоиммунное нарушение. 22. The method of claim 16, wherein the CD4-related condition is an autoimmune disorder. 23. Способ по п.17, где связанным с CD4 состоянием является аутоиммунное нарушение. 23. The method of claim 17, wherein the CD4-related condition is an autoimmune disorder. 24. Способ по п.18, где связанным с CD4 состоянием является аутоиммунное нарушение. 24. The method of claim 18, wherein the CD4-related condition is an autoimmune disorder. 25. Способ по п.19, где связанным с CD4 состоянием является аутоиммунное нарушение. 25. The method of claim 19, wherein the CD4-related condition is an autoimmune disorder. 26. Способ по п.20, где связанным с CD4 состоянием является аутоиммунное нарушение. 26. The method of claim 20, wherein the CD4-related condition is an autoimmune disorder. 27. Способ по п.21, где вышеупомянутое аутоиммунное нарушение представляет собой ревматоидный артрит, воспалительное заболевание кишечника, псориаз, инсулин-зависимый сахарный диабет, системную красную волчанку, цирроз и множественный склероз. 27. The method according to item 21, where the aforementioned autoimmune disorder is rheumatoid arthritis, inflammatory bowel disease, psoriasis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, cirrhosis and multiple sclerosis. 28. Способ по п.22, где вышеупомянутое аутоиммунное нарушение представляет собой ревматоидный артрит, воспалительное заболевание кишечника, псориаз, инсулин-зависимый сахарный диабет, системную красную волчанку, цирроз и множественный склероз. 28. The method according to item 22, where the aforementioned autoimmune disorder is rheumatoid arthritis, inflammatory bowel disease, psoriasis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, cirrhosis and multiple sclerosis. 29. Способ по п.23, где вышеупомянутое аутоиммунное нарушение представляет собой ревматоидный артрит, воспалительное заболевание кишечника, псориаз, инсулин-зависимый сахарный диабет, системную красную волчанку, цирроз и множественный склероз. 29. The method according to item 23, where the aforementioned autoimmune disorder is rheumatoid arthritis, inflammatory bowel disease, psoriasis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, cirrhosis and multiple sclerosis. 30. Способ по п.24, где вышеупомянутое аутоиммунное нарушение представляет собой ревматоидный артрит, воспалительное заболевание кишечника, псориаз, инсулин-зависимый сахарный диабет, системную красную волчанку, цирроз и множественный склероз. 30. The method according to paragraph 24, where the aforementioned autoimmune disorder is rheumatoid arthritis, inflammatory bowel disease, psoriasis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, cirrhosis and multiple sclerosis. 31. Способ по п.25, где вышеупомянутое аутоиммунное нарушение представляет собой ревматоидный артрит, воспалительное заболевание кишечника, псориаз, инсулин-зависимый сахарный диабет, системную красную волчанку, цирроз и множественный склероз. 31. The method according A.25, where the aforementioned autoimmune disorder is rheumatoid arthritis, inflammatory bowel disease, psoriasis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, cirrhosis and multiple sclerosis. 32. Способ по п.17, где вышеупомянутое состояние представляет собой неаутоиммунное нарушение, выбранное из группы, состоящей из лейкоза, лимфомы, реакции "трансплантат против хозяина", астмы, отторжения трансплантата и ВИЧ-инфекции. 32. The method of claim 17, wherein the aforementioned condition is a non-autoimmune disorder selected from the group consisting of leukemia, lymphoma, graft versus host disease, asthma, graft rejection and HIV infection. 33. Способ по п.18, где вышеупомянутое состояние представляет собой неаутоиммунное нарушение, выбранное из группы, состоящей из лейкоза, лимфомы, реакции "трансплантат против хозяина", астмы, отторжения трансплантата и ВИЧ-инфекции. 33. The method of claim 18, wherein the aforementioned condition is a non-autoimmune disorder selected from the group consisting of leukemia, lymphoma, graft versus host disease, asthma, graft rejection and HIV infection. 34. Способ по п.19, где вышеупомянутое состояние представляет собой неаутоиммунное нарушение, выбранное из группы, состоящей из лейкоза, лимфомы, реакции "трансплантат против хозяина", астмы, отторжения трансплантата и ВИЧ-инфекции. 34. The method of claim 19, wherein the aforementioned condition is a non-autoimmune disorder selected from the group consisting of leukemia, lymphoma, graft versus host disease, asthma, graft rejection and HIV infection. 35. Способ по п.20, где вышеупомянутое состояние представляет собой неаутоиммунное нарушение, выбранное из группы, состоящей из лейкоза, лимфомы, реакции "трансплантат против хозяина", астмы, отторжения трансплантата и ВИЧ-инфекции. 35. The method of claim 20, wherein the aforementioned condition is a non-autoimmune disorder selected from the group consisting of leukemia, lymphoma, graft versus host disease, asthma, graft rejection, and HIV infection. 36. Способ по п.21, где вышеупомянутое состояние представляет собой неаутоиммунное нарушение, выбранное из группы, состоящей из лейкоза, лимфомы, реакции "трансплантат против хозяина", астмы, отторжения трансплантата и ВИЧ-инфекции. 36. The method of claim 21, wherein the aforementioned condition is a non-autoimmune disorder selected from the group consisting of leukemia, lymphoma, graft versus host disease, asthma, graft rejection and HIV infection. 37. Способ по п.17, где указанное состояние опосредовано CD4+ клетками или связано с участием CD4+ клеток.37. The method according to 17, where the specified condition is mediated by CD4 + cells or associated with the participation of CD4 + cells.
RU98106117/13A 1995-09-06 1996-09-05 Recombinant antibody against cd4 for human therapy RU2232773C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/523,894 US6136310A (en) 1991-07-25 1995-09-06 Recombinant anti-CD4 antibodies for human therapy
US08/523,894 1995-09-06

Publications (2)

Publication Number Publication Date
RU98106117A true RU98106117A (en) 2000-06-27
RU2232773C2 RU2232773C2 (en) 2004-07-20

Family

ID=24086874

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98106117/13A RU2232773C2 (en) 1995-09-06 1996-09-05 Recombinant antibody against cd4 for human therapy

Country Status (24)

Country Link
US (5) US6136310A (en)
EP (1) EP0854885B1 (en)
JP (1) JP3619866B2 (en)
KR (1) KR100491222B1 (en)
CN (1) CN100391978C (en)
AP (1) AP1193A (en)
AT (1) ATE348113T1 (en)
AU (1) AU717674B2 (en)
BG (1) BG64651B1 (en)
BR (1) BR9610404A (en)
CA (1) CA2231182A1 (en)
CZ (1) CZ291036B6 (en)
DE (1) DE69636760T2 (en)
HK (1) HK1016995A1 (en)
HU (1) HU221351B1 (en)
IL (1) IL123447A0 (en)
MX (1) MX9801732A (en)
NO (1) NO324497B1 (en)
NZ (1) NZ316835A (en)
OA (1) OA10671A (en)
RO (1) RO120198B1 (en)
RU (1) RU2232773C2 (en)
SK (1) SK27998A3 (en)
WO (1) WO1997009351A1 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
WO1998004281A1 (en) * 1996-07-26 1998-02-05 Smithkline Beecham Corpration Improved method of treating immune cell mediated systemic diseases
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
WO1998058966A1 (en) * 1997-06-24 1998-12-30 Norman Godin A composition for specific immunoprotection and method for obtaining said composition
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR100940380B1 (en) * 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001094586A2 (en) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
AR035779A1 (en) * 2001-02-06 2004-07-14 Genetics Inst Llc FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
ATE443131T1 (en) * 2001-07-10 2009-10-15 Biogen Idec Inc INHIBITION OF THE APOPTOSIS PROCESS AND IMPROVEMENT OF CELL PERFORMANCE
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
DK1432431T3 (en) 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
WO2003048306A2 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
US8034351B2 (en) * 2002-04-22 2011-10-11 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
US20040001844A1 (en) * 2002-04-22 2004-01-01 Jan Holgersson Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof
CA2483476A1 (en) * 2002-04-22 2003-10-30 Absorber, Ab Fusion polypeptides and methods for inhibiting microbial adhesion
EA011686B1 (en) * 2002-07-15 2009-04-28 Уайт Method for modulating t helper (t) cell development
NZ538629A (en) * 2002-08-09 2008-05-30 Recopharma Ab Mucin-immunoglobulin fusion proteins
WO2004028473A2 (en) * 2002-09-27 2004-04-08 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
WO2004035537A2 (en) * 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
JP4033390B2 (en) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 Immortalized natural killer cell line
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
JP2007537710A (en) * 2003-06-11 2007-12-27 ワイス Platelet glycoprotein IBα variant fusion polypeptide and use thereof
GB2406094B (en) * 2003-09-17 2007-06-06 Antisoma Plc Modified antibody comprising an amino acid substitution mutation which confers increased stability
CN1902228A (en) * 2003-11-07 2007-01-24 安姆根有限公司 Monkey immunoglobulin sequences
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2006135385A2 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
US7658919B2 (en) * 2004-10-14 2010-02-09 Recopharma Ab Compositions and methods for inhibiting H. pylori adhesion and infection
US7589182B1 (en) 2005-01-07 2009-09-15 Los Alamos National Security, Llc Anti-sulfotyrosine antibodies
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
JP2009514627A (en) * 2005-11-10 2009-04-09 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Reduce restenosis
KR20080082629A (en) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 Hepatocyte growth factor intron fusion proteins
US7495097B2 (en) * 2005-11-23 2009-02-24 Brown University Rhodium quinonoid catalysts
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AU2007208218A1 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
US20090181041A1 (en) * 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
EP2264060B1 (en) 2006-01-26 2014-04-23 Recopharma AB Compositions and methods for inhibiting viral adhesion
MX2008011785A (en) * 2006-03-16 2008-09-25 Genentech Inc Methods of treating lupus using cd4 antibodies.
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2643991A1 (en) 2006-03-23 2007-11-29 Absorber Ab Blood group antigens of different types for diagnostic and therapeutic applications
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
SG172692A1 (en) * 2006-06-12 2011-07-28 Symphogen As Pan-cell surface receptor- specific therapeutics
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CN103214577B (en) 2007-03-22 2015-09-02 生物基因Ma公司 Specific binding CD154 comprises associated proteins of antibody, antibody derivatives and antibody fragment and uses thereof
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
CL2008002092A1 (en) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugate containing two or more antifusogenic peptides and an anti-cd-4 antibody; Method of production; pharmaceutical composition comprising it; antifusogenic polypeptides and use of the conjugate to treat viral infections.
PH12018501459A1 (en) 2007-09-26 2019-11-11 Chugai Pharmaceutical Co Ltd Modified antibody constant region
MX369784B (en) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
WO2009052184A2 (en) * 2007-10-16 2009-04-23 Receptor Biologix, Inc. Compositions comprising optimized her1 and her3 multimers and methods of use thereof
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
ES2610327T3 (en) 2008-03-13 2017-04-27 Biotest Ag Dosing regimen of anti-CD4 antibodies for the treatment of autoimmune diseases
BRPI0909180A2 (en) 2008-03-13 2016-08-09 Biotest Ag pharmaceutical composition and method of treating an autoimmune disease
AU2009231325B2 (en) * 2008-03-13 2014-09-18 Biotest Ag Agent for treating disease
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
CN102015772A (en) * 2008-05-09 2011-04-13 瑞科非玛Ab公司 Compositions and methods for inhibiting shiga toxin and shiga-like toxin
WO2009142759A1 (en) * 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
AR077718A1 (en) * 2008-07-15 2011-09-21 Genentech Inc METHODS TO TREAT AUTOIMMUNE DISEASES USING ANTI CD4 ANTIBODIES. PHARMACEUTICAL FORMULATION
MX2011001583A (en) 2008-08-11 2011-04-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates.
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
MX2011003335A (en) * 2008-09-29 2011-04-27 Biotest Ag Composition for treating disease.
CA2739568C (en) * 2008-10-31 2015-12-01 Shujun Sun Purification of acidic proteins using ceramic hydroxyapatite chromatography
HUE029946T2 (en) 2008-12-26 2017-04-28 Kyowa Hakko Kirin Co Ltd Anti-cd4 antibody
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
FR2945538B1 (en) 2009-05-12 2014-12-26 Sanofi Aventis HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE.
AR076875A1 (en) 2009-05-15 2011-07-13 Chugai Pharmaceutical Co Ltd ANTIBODY AGAINST TYPEOSIN KINASE RECEIVER (ANTI-AXL)
WO2011020079A1 (en) * 2009-08-13 2011-02-17 Calmune Corporation Antibodies against human respiratory syncytial virus (rsv) and methods of use
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
FR2958936A1 (en) 2010-04-14 2011-10-21 Sanofi Aventis ROBO1-FC FUSION PROTEIN AND ITS USE IN THE TREATMENT OF TUMORS
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
CA3062786C (en) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
AU2011347237A1 (en) 2010-12-21 2013-07-11 Recopharma Ab Tear substitutes
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
KR20130132880A (en) 2010-12-23 2013-12-05 사노피 Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX354359B (en) 2011-03-29 2018-02-28 Roche Glycart Ag Antibody fc variants.
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
MX356162B (en) 2012-07-05 2018-05-16 Genentech Inc Expression and secretion system.
HUE056217T2 (en) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013335004B2 (en) 2012-10-22 2018-06-28 Oneness Biotech Co. LTD Antibodies to interleukin-6 and uses thereof
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
WO2014135984A2 (en) 2013-03-07 2014-09-12 Recopharma Ab Glycosylated mucin-immunoglobulin fusion protein coated device
EP3000478A4 (en) * 2013-05-23 2017-03-15 IDAC Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
WO2015006519A1 (en) * 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Departement Of Health &Human Services Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
RU2758952C1 (en) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Method for producing a polypeptide heteromultimer
CN105979961B (en) 2014-02-05 2020-12-18 西达-赛奈医疗中心 Methods and compositions for treating cancer and infectious diseases
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
WO2016159213A1 (en) 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
CN106188292B (en) * 2015-05-05 2019-09-24 北京傲锐东源生物科技有限公司 Anti- CD4 protein monoclonal antibody and application thereof
KR20180091918A (en) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 A method for efficiently purifying the Fc region-containing polypeptide
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3049402A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
CN108690138A (en) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 It is a kind of can be with people CD19 or CD20 and people the CD3 bispecific antibody combined and its application
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019160907A1 (en) * 2018-02-14 2019-08-22 University Of Virginia Patent Foundation Regulating cd4+ t cells to treat clostridium difficile infection
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
CN113248612A (en) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 Use of anti-PD-1 antibodies in the treatment of neuroendocrine tumors
CN113244386A (en) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 Use of anti-PD-1 antibodies in the treatment of tumors
CN113045661B (en) * 2021-04-07 2022-06-21 中美冠科生物技术（太仓）有限公司 Novel anti-CD 4 antibodies
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
DE3814887C1 (en) * 1988-05-02 1989-09-21 Medice Chem.-Pharm. Fabrik Puetter Gmbh & Co Kg, 5860 Iserlohn, De
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH04504842A (en) * 1989-01-18 1992-08-27 プレジデント アンド フェローズ オブ ハーバード カレッジ Compositions and methods for the treatment or prevention of AIDS, ARC and HIV infection
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
JP3502093B2 (en) * 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド Production of antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE69233011T2 (en) * 1991-07-25 2003-11-06 Idec Pharma Corp RECOMBINANT ANTIBODIES FOR HUMAN THERAPY
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US5691183A (en) * 1993-07-07 1997-11-25 University Technology Corporation CD4+ T-lymphoctye proteases and genes encoding said proteases

Similar Documents

Publication Publication Date Title
RU98106117A (en) RECOMBINANT ANTIBODIES AGAINST CD4 FOR HUMAN THERAPY
RU2007102079A (en) ALPHA INTERFERON RECEPTOR ANTIBODIES AND THEIR APPLICATION
Li et al. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses
Farstad et al. Distribution of β7 integrins in human intestinal mucosa and organized gut‐associated lymphoid tissue
Segerer et al. B cells and tertiary lymphoid organs in renal inflammation
JP2001517425A5 (en)
RU2003125266A (en) Fused Proteins Binding Domain-Immunoglobulin
EP0572118A1 (en) Monoclonal antibodies to GP130 protein
RU96115107A (en) "HUMAN" ANTIBODIES AND THEIR USE
KR960706560A (en) HUMANIZED ANTIBODIES AND USES THEREOF
KR910700350A (en) Chimeric Immunoglobulins Specific for the P_55 TAC Protein of the IL-2 Receptor
JP2004500320A5 (en)
Allende et al. A point mutation in a domain of gamma interferon receptor 1 provokes severe immunodeficiency
KR900700606A (en) Cloned Genes Encoding IG-CD4 Fusion Proteins and Their Uses
NZ251343A (en) Monoclonal antibodies directed at human interferon class 1 receptor
KR920701465A (en) CD4-specific recombinant antibody
ATE185351T1 (en) A HUMAN MONOCLONAL IGG-1 ANTIBODY REACTING WITH HIV-1 GLYCOPROTEIN AND METHOD OF USE
RU99112112A (en) IDENTIFICATION OF UNIQUE TYPES OF INTERACTION BETWEEN SOME ANTIBODIES AND CO-STIMULATING HUMAN ANTIGENS B7.1 and B7.2
Bogen et al. A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype‐specific, major histocompatibility complex‐restricted T cell clones
Hoshino et al. Flow cytometric analysis of expression of interleukin-2 receptor beta chain (p70-75) on various leukemic cells
Yoshie et al. Interferon action: Effects of mouse α and β interferons on rosette formation, phagocytosis, and surface-antigen expression of cells of the macrophage-type line RAW 309Cr. 1
JP2002538814A5 (en)
Suzuki et al. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody
WO1995007716A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US20020037934A1 (en) Method for treating hepatitis